16th Aug 2018 10:59
LONDON (Alliance News) - SkinBioTherapeutics PLC said Thursday that it achieved "significant" manufacturing scale-up alongside its third party manufacturer.
The company added that it has successfully manufactured and freeze dried the material it used to supply in a liquid form.
"The ability to freeze dry the material is an important steps towards commercialisation as it enables mass production, storage and transportation," the company explained.
SkinBioTherapeutics is scheduled to commence a human study to confirm the stability over the long-term of the SkinBiotix technology in cream formulation. The cream has shown stability for 24 hours.
Shares were trading 10% lower at 21.50 pence each.
Related Shares:
Skinbiotherap.